Authors: Sharon Salt, Editor
Earlier this week at the American Academy of Neurology’s (AAN) 70th Annual Meeting (21–27 April, CA, USA), neurologists from Penn Medicine (PA, USA) have presented their findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis (MS) patients.Restricted Content / Members Only
Restricted Content / Members Only